The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old
Yıl: 2022 Cilt: 14 Sayı: 2 Sayfa Aralığı: 196 - 206 Metin Dili: İngilizce DOI: 10.4274/jcrpe.galenos.2022.2021-10-4 İndeks Tarihi: 05-07-2022
The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old
Öz: Objective: This study aimed to evaluate the role of risk stratification by the American Thyroid Association (ATA) pediatric thyroid cancer
risk levels and BRAFV600E mutation to predict the response to treatment in papillary thyroid cancer (PTC) patients ≤18 years old.
Methods: Clinical outcomes during a median period of 6 (2-21.8) years were assessed in 70 patients, according to ATA pediatric risk
stratification, BRAFV600E mutation status, and dynamic risk stratification (DRS) at final follow-up.
Results: Of 70 patients, 44 (63%), 14 (20%), and 12 (17%) were classified initially as low-, intermediate-, and high-risk, respectively.
BRAFV600E mutation analysis data was available in 55 (78.6%) patients, of whom 18 (32.7%) had the BRAFV600E mutation. According to
the final DRS, 61 (87%), two (3%), six (9%), and one (1%) patients were classified as an excellent, incomplete biochemical, incomplete
structural, and indeterminate response, respectively. All ATA low-risk patients showed excellent response to treatment, whereas the rate
of excellent response was 65.4% in intermediate- and high-risk levels (p<0.001). The rates of excellent response in BRAFV600E positive
and negative patients were 83% and 92%, respectively (p=0.339). The rate of locoregional recurrence was significantly higher in
BRAFV600E positive vs negative patients (33.3% vs 2.7% respectively, p=0.001).
Conclusion: ATA pediatric risk stratification is effective in predicting response to treatment in PTC patients ≤18 years old. The presence
of BRAFV600E mutation was highly predictive for recurrence but had no significant impact on the rate of excellent response to treatment
at final follow-up.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, Dinauer CA, Hamilton J, Hay ID, Luster M, Parisi MT, Rachmiel M, Thompson GB, Yamashita S; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2015;25:716-759.
- 2. Drozd V, Saenko V, Branovan DI, Brown K, Yamashita S, Reiners C. A search for causes of rising incidence of differentiated thyroid cancer in children and adolescents after Chernobyl and Fukushima: Comparison of the clinical features and their relevance for treatment and prognosis. Int J Environ Res Public Health 2021;18:3444.
- 3. Vaccarella S, Lortet-Tieulent J, Colombet M, Davies L, Stiller CA, Schüz J, Togawa K, Bray F, Franceschi S, Dal Maso L, Steliarova-Foucher E; IICC- 3 contributors. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study. Lancet Diabetes Endocrinol 2021;9:144-152. Epub 2021 Jan 19
- 4. Bleyer WA. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol 2002;38:1-10.
- 5. Bernier MO, Withrow DR, Berrington de Gonzalez A, Lam CJK, Linet MS, Kitahara CM, Shiels MS. Trends in pediatric thyroid cancer incidence in the United States, 1998-2013. Cancer 2019;125:2497-2505. Epub 2019 Apr 23
- 6. Rivkees SA, Mazzaferri EL, Verburg FA, Reiners C, Luster M, Breuer CK, Dinauer CA, Udelsman R. The treatment of differentiated thyroid cancer in children: Emphasis on surgical approach and radioactive iodine therapy. Endocr Rev 2011;32:798-826. Epub 2011 Aug 31
- 7. Qian ZJ, Jin MC, Meister KD, Megwalu UC. Pediatric thyroid cancer ıncidence and mortality trends in the United States, 1973-2013. JAMA Otolaryngol Head Neck Surg 2019;145:617-623.
- 8. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
- 9. Amin M, Edge S, Greene F. AJCC cancer staging manual. 8th. New York, Springer, 2017.
- 10. Karapanou O, Tzanela M, Rondogianni P, Dacou-Voutetakis C, Chiotis D, Vlassopoulou B, Vassiliadi D, Kanaka-Gantenbein C, Tsagarakis S. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of preablation stimulated thyroglobulin as predictors of disease persistence. Endocrine 2020;70:566-574. Epub 2020 Jun 13
- 11. Pires BP, Alves PA Jr, Bordallo MA, Bulzico DA, Lopes FP, Farias T, Dias F, Lima RA, Santos Gisler IC, Coeli CM, Carvalhaes de Oliveira RV, Corbo R, Vaisman M, Vaisman F. Prognostic factors for early and longterm remission in pediatric differentiated thyroid carcinoma: The role of sex, age, clinical presentation, and the newly proposed American Thyroid Association Risk Stratification System. Thyroid 2016;26:1480- 1487. Epub 2016 Sep 22
- 12. Lazar L, Lebenthal Y, Segal K, Steinmetz A, Strenov Y, Cohen M, Yaniv I, Yackobovitch-Gavan M, Phillip M. Pediatric thyroid cancer: postoperative classifications and response to ınitial therapy as prognostic factors. J Clin Endocrinol Metab 2016;101:1970-1979. Epub 2016 Mar 1
- 13. Sung TY, Jeon MJ, Lee YH, Lee YM, Kwon H, Yoon JH, Chung KW, Kim WG, Song DE, Hong SJ. Initial and dynamic risk stratification of pediatric patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2017;102:793-800.
- 14. Kim K, Kim WW, Choi JB, Kim MJ, Lee CR, Lee J, Kang SW, Nam KH, Chung WY, Jeong JJ. Usefulness of dynamic risk stratification in pediatric patients with differentiated thyroid carcinoma. Ann Surg Treat Res 2018;95:222-229. Epub 2018 Sep 28
- 15. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables tomodify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 2010;20:1341-1349. Epub 2010 Oct 29
- 16. Vaisman F, Momesso D, Bulzico DA, Pessoa CH, Dias F, Corbo R, Vaisman M, Tuttle RM. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf) 2012;77:132-138.
- 17. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 2011;165:441-446. Epub 2011 Jul 12
- 18. Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American Thyroid Association and Latin American Thyroid Society risk of recurrence classification systems. Thyroid 2013;23:1401-1407. Epub 2013 Jul 25
- 19. Zanella AB, Scheffel RS, Nava CF, Golbert L, Laurini de Souza Meyer E, Punales M, Gonçalves I, Dora JM, Maia AL. Dynamic risk stratification in the follow-up of children and adolescents with differentiated thyroid cancer. Thyroid 2018;28:1285-1292.
- 20. Sohn SY, Kim YN, Kim HI, Kim TH, Kim SW, Chung JH. Validation of dynamic risk stratification in pediatric differentiated thyroid cancer. Endocrine 2017;58:167-175. Epub 2017 Aug 18
- 21. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: A systematic review and meta-analysis. Medicine (Baltimore) 2012;91:274-286.
- 22. Wang Z, Chen JQ, Liu JL, Qin XG. Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: A systematic review and meta-analysis. Eur J Clin Invest 2016;46:146- 157. Epub 2016 Jan 18
- 23. Galuppini F, Vianello F, Censi S, Barollo S, Bertazza L, Carducci S, Colato C, Manso J, Rugge M, Iacobone M, Watutantrige Fernando S, Pennelli G, Mian C. Differentiated thyroid carcinoma in pediatric age: Genetic and clinical scenario. Front Endocrinol (Lausanne) 2019;10:552.
- 24. Geng J, Wang H, Liu Y, Tai J, Jin Y, Zhang J, He L, Fu L, Qin H, Song Y, Su J, Zhang A, Wen X, Guo Y, Ni X. Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma. Sci China Life Sci 2017;60:729-738. Epub 2017 Jun 15
- 25. Hardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic characteristics, natural history, and prognostic ımplications of BRAFV600E mutation in pediatric papillary thyroid carcinoma. Pediatr Dev Pathol 2017;20:206-212. Epub 2017 Feb 8
- 26. Poyrazoğlu Ş, Bundak R, Baş F, Yeğen G, Şanlı Y, Darendeliler F. Clinicopathological characteristics of papillary thyroid cancer in children with emphasis on pubertal status and association with BRAF V600E mutation. J Clin Res Pediatr Endocrinol 2017;9:185-193. Epub 2017 Jan 12
- 27. Nikita ME, Jiang W, Cheng SM, Hantash FM, McPhaul MJ, Newbury RO, Phillips SA, Reitz RE, Waldman FM, Newfield RS. Mutational analysis in pediatric thyroid cancer and correlations with age, ethnicity, and clinical presentation. Thyroid 2016;26:227-234. Epub 2016 Jan 7
- 28. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 2011;50:307-312. Epub 2011 Feb 8
- 29. Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014;43:401-421.
- 30. Grigsby PW, Gal-or A, Michalski JM, Doherty GM. Childhood and adolescent thyroid carcinoma. Cancer 2002;95:724-729.
- 31. Henke LE, Perkins SM, Pfeifer JD, Ma C, Chen Y, DeWees T, Grigsby PW. BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer 2014;61:1168-1172. Epub 2014 Mar 27
- 32. Tunca F, Sormaz IC, Iscan Y, Senyurek YG, Terzioglu T. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. J Endocrinol Invest 2015;38:1327- 1334. Epub 2015 Aug 18
- 33. Givens DJ, Buchmann LO, Agarwal AM, Grimmer JF, Hunt JP. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope 2014;124:389-393. Epub 2014 Apr 29
- 34. Lerner J, Goldfarb M. Follicular variant papillary thyroid carcinoma in a pediatric population. Pediatr Blood Cancer 2015;62:1942-1946. Epub 2015 Jul 1
- 35. Welch Dinauer CA, Tuttle RM, Robie DK, McClellan DR, Svec RL, Adair C, Francis GL. Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf) 1998;49:619-628.
- 36. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullarythyroid cancer: A review. Thyroid 2002;12:683-702.
- 37. Demidchik YE, Demidchik EP, Reiners C, Biko J, Mine M, Saenko VA, Yamashita S. Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 2006;243:525-532.
- 38. Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulska A, Prokurat A, Wygoda Z, Jarzab B. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 2007;48:879-888.
- 39. O’Gorman CS, Hamilton J, Rachmiel M, Gupta A, Ngan BY, Daneman D. Thyroid cancer in childhood: A retrospective review of childhood course. Thyroid 2010;20:375-380.
| APA | şenyürek y, Iscan Y, Sormaz İ, Poyrazoglu S, Tunca F (2022). The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. , 196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| Chicago | şenyürek yasemin,Iscan Yalin,Sormaz İsmail Cem,Poyrazoglu Sukran,Tunca Fatih The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. (2022): 196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| MLA | şenyürek yasemin,Iscan Yalin,Sormaz İsmail Cem,Poyrazoglu Sukran,Tunca Fatih The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. , 2022, ss.196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| AMA | şenyürek y,Iscan Y,Sormaz İ,Poyrazoglu S,Tunca F The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. . 2022; 196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| Vancouver | şenyürek y,Iscan Y,Sormaz İ,Poyrazoglu S,Tunca F The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. . 2022; 196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| IEEE | şenyürek y,Iscan Y,Sormaz İ,Poyrazoglu S,Tunca F "The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old." , ss.196 - 206, 2022. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| ISNAD | şenyürek, yasemin vd. "The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old". (2022), 196-206. https://doi.org/10.4274/jcrpe.galenos.2022.2021-10-4 |
| APA | şenyürek y, Iscan Y, Sormaz İ, Poyrazoglu S, Tunca F (2022). The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. Journal of Clinical Research in Pediatric Endocrinology, 14(2), 196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| Chicago | şenyürek yasemin,Iscan Yalin,Sormaz İsmail Cem,Poyrazoglu Sukran,Tunca Fatih The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. Journal of Clinical Research in Pediatric Endocrinology 14, no.2 (2022): 196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| MLA | şenyürek yasemin,Iscan Yalin,Sormaz İsmail Cem,Poyrazoglu Sukran,Tunca Fatih The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. Journal of Clinical Research in Pediatric Endocrinology, vol.14, no.2, 2022, ss.196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| AMA | şenyürek y,Iscan Y,Sormaz İ,Poyrazoglu S,Tunca F The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. Journal of Clinical Research in Pediatric Endocrinology. 2022; 14(2): 196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| Vancouver | şenyürek y,Iscan Y,Sormaz İ,Poyrazoglu S,Tunca F The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old. Journal of Clinical Research in Pediatric Endocrinology. 2022; 14(2): 196 - 206. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| IEEE | şenyürek y,Iscan Y,Sormaz İ,Poyrazoglu S,Tunca F "The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old." Journal of Clinical Research in Pediatric Endocrinology, 14, ss.196 - 206, 2022. 10.4274/jcrpe.galenos.2022.2021-10-4 |
| ISNAD | şenyürek, yasemin vd. "The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and BRAFV600E Mutation in Predicting the Response to Treatment in Papillary Thyroid Cancer Patients ≤18 Years Old". Journal of Clinical Research in Pediatric Endocrinology 14/2 (2022), 196-206. https://doi.org/10.4274/jcrpe.galenos.2022.2021-10-4 |
